[Biochemical aspects of the effect of L-dopa in patients with Parkinson's disease].
D003545:Cysteine / Q000134:cerebrospinal fluid; D003553:Cystine / Q000134:cerebrospinal fluid; D004295:Dihydroxyphenylalanine / Q000627:therapeutic use*; D005260:Female; D005998:Glycine / Q000134:cerebrospinal fluid; D006801:Humans; D008297:Male; D008715:Methionine / Q000134:cerebrospinal fluid; D010300:Parkinson Disease / Q000134:cerebrospinal fluid / Q000188:drug therapy*; D012694:Serine / Q000134:cerebrospinal fluid; D013912:Threonine / Q000134:cerebrospinal fluid; D013997:Time Factors
D013912:Threonine; D012694:Serine; D003553:Cystine; D004295:Dihydroxyphenylalanine; D008715:Methionine; D003545:Cysteine; D005998:Glycine
Biochemische Aspekte der L-DOPA-Wirkung bei Parkinsonpatienten.